Related Experiment Video
Updated: Apr 18, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Donepezil-ferulic acid hybrids as anti-Alzheimer drugs
Mohamed Benchekroun1, Lhassane Ismaili, Marc Pudlo
1NanoMedicine, Imagery & Therapeutics Lab EA 4662, Laboratoire de Chimie Organique et Thérapeutique UFR SMP, CHU Jean Minjoz, Université de Franche-Comté, 19 rue Ambroise Paré, 25030-Besançon, France.
Background:
Due to the complex nature of Alzheimer's disease, there is a renewed and growing search for multitarget drugs.
Results:
Donepezil-ferulic acid hybrids (DFAHs) were prepared by the one-pot Ugi-4CR in low-to-moderate yields. DFAHs are potent antioxidant agents, showing oxygen radical absorbance capacity values in the range 4.80-8.71 trolox equivalents, quite higher compared with those recorded for ferulic acid and melatonin. From the ChEs inhibition studies, we conclude that DFAH 8, bearing an ethylene linker, and DFAH 12, bearing a propylene linker, both substituted with a melatonin motif, are the most potent inhibitors, in the nanomolar range.
Conclusion:
We have identified DFAH 8 as a very potent antioxidant, and totally selective equineButyrylCholinEsterase (eqBuChE) inhibitor.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction

